A Christmas Message to the DEA’s Diversion Anti Marijuana Cabal 
SS Innovations to Participate in Upcoming Investor Conferences
FORT LAUDERDALE, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII),...
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical...
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to...
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously...
Sienna Announces The Opening of Its Long-Term Care Community Redevelopment in Brantford, Ontario
MARKHAM, Ontario, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) announced today...
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly...
Notice convening an Extraordinary General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 21 October 2025 – Further to company announcement no. 28 issued today, an Extraordinary General Meeting of Novo...
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit
Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21,...
InnovAge to Announce Fiscal First Quarter 2026 Financial Results and Host Conference Call Tuesday, November 4, 2025
DENVER, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in...
Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025
PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report...
Avalyn Announces Multiple Presentations at the Pulmonary Fibrosis Foundation (PFF) Summit 2025
Presentations to Highlight Patient Experience Research, AURA-IPF Phase 2 Trial Design for AP02, and Long-Term Safety Data for AP01BOSTON, Oct....
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET
REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel...
Medical Specialists of the Palm Beaches Unveils State-of-the-Art Medical Facility in Wellington, Florida
WELLINGTON, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Medical Specialists of the Palm Beaches (MSPB), a primary care-focused, multi-specialty physician...
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of...
Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak®...
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension...
AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure
Research Triangle Park, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- First-in-human trial of investigational gene therapy AB-1002 designed to evaluate...
Solenic Medical Announces Successful Use of Its AMF Technology Under FDA Compassionate Use Authorization
Company to Exhibit at American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting 2025DALLAS, Oct. 21, 2025 (GLOBE NEWSWIRE)...